IPAMORELIN
Solid pharmacological profile with reliable GH stimulation, but clinical outcomes remain largely theoretical. The mechanism works as advertised, yet actual health benefits haven't been proven in rigorous human trials.
Anti-aging clinics and longevity researchers favor this peptide for growth hormone studies where isolating GH effects from other hormonal influences is crucial.
Since Feb 2026
19 total, 1 human
#6 most researched
What is IPAMORELIN?
Among the growth hormone-releasing peptides, this compound stands out for its surgical precision in triggering GH release without the hormonal chaos that plagues other peptides in this class. Unlike broader GHRPs that can spike cortisol or prolactin, ipamorelin hits only its intended target, making it a favorite among researchers studying growth hormone's isolated effects.
This peptide works by binding specifically to ghrelin receptors in the pituitary gland, which then signals the release of growth hormone in clean, predictable pulses. Think of it as a highly selective key that opens only the growth hormone door, leaving other hormonal pathways untouched—unlike cruder peptides that kick down multiple doors at once.
What the Research Shows
19 studies provide good pharmacokinetic data and confirm the GH-releasing mechanism, but only 2 randomized controlled trials exist, and clinical benefit studies have been disappointing.
Across 19 total studies (5 human, 2 RCTs), ipamorelin demonstrated dose-proportional pharmacokinetics with potent growth hormone stimulation and a 2-hour half-life, but showed no significant clinical benefit over placebo for postoperative ileus and lacks sufficient evidence for orthopedic applications. Safety data indicate good tolerability in human studies, though detection of ipamorelin and related GHRPs in black market products and varying urinary detection windows raise concerns about illicit use and analytical challenges.
Notable Studies
Beck DE, Sweeney WB, McCarter MD et al. · Int J Colorectal Dis (2014)
RCT · Phase 2 · n=114 · 7 days
Gobburu JV, Agersø H, Jusko WJ et al. · Pharm Res (1999)
RCT · Phase 1 · n=40 · Single dose escalation study
Semenistaya E, Zvereva I, Thomas A et al. · Drug Test Anal (2015)
Case Series · n=52 · days post-administration
Timms M, Hall N, Levina V et al. · Drug Test Anal (2014)
Animal
Johansen PB, Segev Y, Landau D et al. · Exp Diabesity Res (2003)
Animal · 14 days
Reported Benefits
Combinations & Interactions
Regulatory Status
Last verified: Feb 2026
Related Peptides
This information is for research purposes only and does not constitute medical advice. Always consult a licensed physician before using any peptides.